近期，2024法国癌证研究探讨研究会（AACR）公司年会在法国聖地亚哥立即耗时4月10日完美收官落下帷幕，集萃ob电竞官网入口
在这一次办公会议上展现出了7张宣传海报，产生了列席者的浓烈座谈。
集萃ob电竞官网入口
展示的海报内容涵盖免疫重建小鼠模型、Enhertu耐药肿瘤模型、治疗性抗体的临床前评估、HER2靶向药物、IL-12临床前药物研发、人源化抗体领域小鼠模型、临床前PD-1耐药模型这7项研究成果：
01 Preclinical PD-1 Resistance Models: Crucial Tools for Unveiling PD-1 Resistance Mechanisms and Advancing Novel Treatment Strategies
02 NeoMab™: A Novel Platform for Fully Human Therapeutic Antibody Development
03 Patient-derived xenograft (PDX) models with differential HER2 expression for preclinical evaluation of HER2-targeted therapies
04 Development of a Novel Murine Model, NCG-M/hIL15, for Enhanced Post-HSC Transplantation Immunoreconstruction
05 Development and Application of the NCG-hIL2 Mouse Model: A Humanized Platform for Enhanced NK Cell Evaluation in ADCC Efficacy Testing
06 BALB/c-hIL12RB1/hIL12RB2: A Robust Model for Preclinical Research in Human IL-12 Therapy
07 Breaking Through ADCs Resistance: Constructing Preclinical Enhertu-induced Resistant Model
您可双击留言板链接转换下载地址集萃ob电竞官网入口
AACR 2024海报设计：
